Methadone

Introduction Overview

Generic Name

methadone

Brand Name

Dolophine, Methadose, Methadose Sugar-Free, Diskets

Dosage Form

injectable solution, intravenous solution, oral concentrate, oral solution, oral tablet, dispersible tablet

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Absorption: Methadone is well absorbed orally, with bioavailability ranging from 36% to 100%, largely depending on individual patient factors such as gastrointestinal motility and pH. Peak plasma concentrations are generally reached within 2 to 4 hours post-oral administration. Oral dosing is favored in opioid maintenance therapy due to its convenience and steady absorption. Food does not significantly affect methadone absorption. Variability in absorption requires careful dose titration and monitoring.

Distribution: Methadone has extensive tissue distribution due to its high lipophilicity. It exhibits a large volume of distribution (Vd) ranging from 2 to 6 L/kg, reflecting widespread distribution throughout body tissues, including the brain, lungs, liver, kidneys, and fat stores. Methadone is approximately 85-90% protein bound, predominantly to alpha-1-acid glycoprotein. This extensive tissue binding aids in its prolonged duration of action and long elimination half-life, which can vary widely (8-59 hours), leading to accumulation with repeated dosing.

Metabolism: Methadone undergoes hepatic metabolism primarily via cytochrome P450 enzymes CYP3A4, CYP2B6, CYP2D6, and to a lesser extent CYP1A2 and CYP2C19. The metabolism involves N-demethylation producing inactive metabolites such as 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). Interindividual variability in CYP enzyme activity significantly affects methadone metabolism, leading to differences in plasma levels and risk of toxicity or withdrawal. Co-administration of CYP inhibitors or inducers can alter methadone plasma concentrations, necessitating dosage adjustments.

Elimination: Methadone is eliminated primarily via metabolism with less than 10% excreted unchanged renally. The metabolites are eliminated in urine and feces. The elimination half-life is prolonged and variable, ranging between 8 and 59 hours, averaging approximately 24 hours, which supports its suitability for once-daily dosing in maintenance therapy. Renal impairment has limited effect on methadone clearance but may affect metabolite elimination. The long and variable half-life poses risks for drug accumulation and overdose, especially during initiation or dose escalation. Monitoring for signs of toxicity is essential during early therapy.

Dosage Forms

Available Dosage Forms:
- Oral Tablet: Immediate-release tablets in doses commonly including 5 mg and 10 mg.
- Dispersible Tablet: Methadone Diskets, which dissolve in water, orange juice, or citrus-flavored beverages for patients with swallowing difficulties.
- Oral Solution: Concentrated solutions for oral administration.
- Oral Concentrate: Solutions with higher concentration for accurate dosing.
- Injectable Solution: Available for intravenous (IV), intramuscular (IM), or subcutaneous (SC) use.

Dosages for Adults and Adolescents:
- For opioid addiction treatment, initial dosing is individualized, often starting at 10-30 mg orally once daily, carefully titrated to suppress withdrawal symptoms without causing sedation.
- For pain management, methadone is reserved for moderate to severe chronic pain requiring continuous, long-term opioid treatment. Dosages vary widely, generally starting at low doses with careful titration.
- Due to methadone’s long half-life and accumulation potential, dosage adjustments are made slowly and with frequent monitoring.

Specific Patient Populations:
- Elderly: Dose adjustments often necessary due to altered pharmacokinetics and increased sensitivity to respiratory depression.
- Renal Impairment: No significant dosage adjustment necessary; however, caution is advised.
- Hepatic Impairment: Dose reduction may be required since methadone metabolism predominantly occurs in the liver.
- Pregnancy: Use only if benefits outweigh risks; neonates may experience withdrawal syndrome post-delivery.
- Pediatric Use: Safety and efficacy not well established; used under strict supervision in specialized settings.

Clinical Guidelines:
- Methadone for opioid use disorder should be dispensed only through certified opioid treatment programs under strict medical supervision.
- Dispersible tablets and oral solutions provide versatility for dosing in patients with swallowing difficulties or requiring titration.

Mechanism Of Action

Methadone acts primarily as a full agonist at the mu-opioid receptor (MOR), which is a G-protein coupled receptor predominantly located in the central nervous system and gastrointestinal tract. Activation of MOR by methadone leads to inhibition of adenylate cyclase activity, decreased intracellular cyclic AMP, and subsequent inhibition of voltage-gated calcium channels coupled with activation of inwardly rectifying potassium channels. These effects reduce neuronal excitability and neurotransmitter release, resulting in analgesia, sedation, and respiratory depression.

Beyond MOR agonism, methadone also antagonizes the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor involved in pain transmission and central sensitization. NMDA receptor antagonism contributes to methadone's efficacy in neuropathic pain and reduces development of opioid tolerance, distinguishing it from other pure opioid agonists.

Methadone's dual action at the MOR and NMDA receptors, along with its long half-life, provide sustained opioid receptor activation contributing to its role in opioid substitution therapy to suppress withdrawal and cravings without producing significant euphoria when dosed appropriately. This unique pharmacological profile makes methadone effective both in opioid dependence management and chronic pain control.

Clinical evidence supports methadone’s efficacy in reducing illicit opioid use, decreasing opioid craving, and improving retention in treatment programs. Comparative studies demonstrate methadone's advantages in some patients over other opioids due to its NMDA antagonism and longer duration. However, its long and variable half-life necessitates careful clinical monitoring to avoid accumulation and associated toxicities, including life-threatening respiratory depression and QT prolongation.

Pharmacological Actions

Full agonist at mu-opioid receptors leading to analgesic and euphoric effects.
N-methyl-D-aspartate (NMDA) receptor antagonism reducing central sensitization and opioid tolerance.
Inhibition of neurotransmitter release via decreased cyclic AMP signaling in nerve terminals.
Prolongation of opioid receptor activation due to long elimination half-life.
Suppression of opioid withdrawal symptoms by mitigation of withdrawal-induced neuronal hyperexcitability.
Reduction of opioid cravings facilitating opioid use disorder treatment.
Sedative and respiratory depressant effects mediated through central nervous system activity.
Modulation of gastrointestinal motility leading to constipation common with opioid use.
Influence on cardiac ion channels causing QT interval prolongation in susceptible individuals.
Minimal active metabolites, reducing variability in pharmacodynamics.
Cross-tolerance with other opioids due to shared receptor pathway.
Potential inhibition of serotonin reuptake contributing to serotonin syndrome risk when combined with serotonergic drugs.

Therapeutic Or Clinical Uses

Maintenance therapy in opioid use disorder to reduce withdrawal symptoms and cravings.
Chronic moderate to severe pain management requiring long-term opioid treatment.
Management of opioid dependence in approved opioid treatment programs.
Adjunct therapy in neuropathic pain conditions due to NMDA receptor antagonism.
Use in controlled settings to facilitate opioid detoxification.
Treatment of opioid withdrawal symptoms in acute care settings under supervision.
Alternative analgesic option in patients with intolerance to other opioids.
Opioid substitution in patients with history of intravenous drug use to reduce injecting behavior.
Alleviation of opioid-induced hyperalgesia by NMDA receptor blockade.
Use in patients where oral opioid formulations are preferred due to sustained action.
Potential off-label use in refractory cancer pain.
Use in combination therapy with naloxone for opioid dependence management.
Emergency treatment of opioid overdose with naloxone as antidote.
Research consideration for methadone's role in opioid receptor modulation in neuropsychiatric disorders.

Side Or Adverse Effects

Respiratory depression, which can be fatal especially with dose escalation or concomitant depressants.
QT interval prolongation leading to risk of torsades de pointes and sudden cardiac death.
Dizziness and drowsiness impairing cognitive and motor function.
Nausea and vomiting common during initiation or dose adjustments.
Constipation due to decreased gastrointestinal motility.
Sweating and other autonomic disturbances.
Potential for withdrawal symptoms if abruptly discontinued.
Risk of serotonin syndrome when combined with serotonergic agents.
Headache, including migraine-like symptoms associated with opioid use.
Tachycardia or palpitations in susceptible individuals.
Hypotension in some cases, especially when standing (orthostatic hypotension).
Allergic reactions including rash, hives, and rarely anaphylaxis.
Injection site reactions such as pain, redness, or swelling with parenteral use.
Hormonal dysregulation including adrenal insufficiency leading to fatigue and weakness.
Tolerance and physical dependence with chronic use.

Precautions

Use with caution in patients with history of cardiac arrhythmias or prolonged QT syndrome.
Monitor respiratory function, especially in elderly, debilitated, or those with chronic respiratory disease.
Avoid abrupt discontinuation to prevent withdrawal syndrome; taper doses gradually under supervision.
Regular ECG monitoring advised during prolonged treatment or dose escalation.
Cautious use in patients with liver or kidney impairment due to altered metabolism and clearance.
Inform prescribing clinicians about all concomitant medications to assess for drug interactions.
Avoid use with CNS depressants such as benzodiazepines and alcohol to reduce overdose risk.
Pregnant women should be counseled about neonatal opioid withdrawal syndrome and monitored closely.
Assess for risk of misuse, abuse, and diversion due to high addiction potential.
Use caution in patients with head injury, brain tumors, or seizure disorders due to CNS effects.
Monitor for signs of serotonin syndrome when used with serotonergic drugs.
Patients should avoid operating machinery or driving until effects are known.
Patients should store medication securely to prevent accidental ingestion especially by children.
Evaluate adrenal function if symptoms of adrenal insufficiency appear during therapy.
Methadone should only be used in opioid-tolerant patients when used for pain management.

Warnings

Methadone misuse can result in addiction, overdose, or death, especially in individuals not prescribed the drug.
Fatal respiratory depression can occur even with therapeutic doses.
Potential for life-threatening cardiac arrhythmias due to QT prolongation requires cardiac monitoring.
Use during pregnancy can cause neonatal opioid withdrawal syndrome requiring specialized neonatal care.
Concomitant use with alcohol or other CNS depressants increases risk of fatal respiratory depression.
Serotonin syndrome is a risk when combined with serotonergic medications.
Do not share medication; diversion and misuse are illegal and dangerous.
Keep out of reach of children; a single dose can be fatal if taken accidentally.
Advance warning required for dose adjustments due to methadone's long half-life and accumulation risk.
High risk of overdose during induction and dose escalation phases.
Use with caution in patients with compromised respiratory function or sleep apnea.
Sudden discontinuation can precipitate severe withdrawal symptoms.
Injection formulations should only be used by healthcare providers to avoid misuse.
Patients should be monitored for sedation and cognitive impairment.
Naloxone should be readily available for emergency opioid overdose reversal.

Contraindication

Known hypersensitivity or allergy to methadone or any opioid component.
Severe respiratory depression or airway obstruction.
Acute or severe bronchial asthma or hypercarbia in unmonitored settings.
Paralytic ileus or gastrointestinal obstruction due to opioid effects on motility.
Concomitant use of MAO inhibitors within the last 14 days.
Severe CNS depression or coma.
Known or suspected prolonged QT interval or history of torsades de pointes.
Use in patients with significant hepatic impairment without careful monitoring.
Use in patients with severe hypotension or circulatory shock.
Use in patients with acute alcoholism or delirium tremens.
Conditions where opioids are contraindicated for respiratory or neurological reasons.
Concurrent use with other substances known to prolong QT interval without monitoring.
Lactation when risks outweigh benefits and alternative analgesics are available.
Use in non-opioid-tolerant individuals for chronic pain due to risk of overdose.
Use in patients with seizure disorders unless benefit outweighs risk.

Drug Interactions

Concomitant use with other CNS depressants including benzodiazepines, barbiturates, and alcohol increases risk of respiratory depression and death.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin) can increase methadone plasma levels, leading to toxicity.
CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can decrease methadone levels, risking withdrawal symptoms.
Serotonergic drugs such as SSRIs, SNRIs, triptans, or MAO inhibitors increase risk of serotonin syndrome.
Other QT-prolonging agents (e.g., antiarrhythmics, antipsychotics) can exacerbate cardiac arrhythmia risk.
Antiretroviral drugs, especially protease inhibitors and non-nucleoside reverse transcriptase inhibitors, may alter methadone metabolism.
Medications for allergies, asthma, blood pressure, and overactive bladder can have additive sedative effects.
Muscle relaxants and sleep aids may potentiate CNS depression.
Opioid antagonists like naloxone can antagonize methadone's effects and precipitate withdrawal.
Use with other opioids increases risk of additive respiratory depression and overdose.
St. John's Wort and other herbal CYP inducers may reduce methadone efficacy.
Drugs affecting gastric pH may alter methadone absorption.
Macrolide antibiotics can inhibit CYP enzymes, increasing methadone plasma concentration.
Fluoxetine and paroxetine (CYP2D6 inhibitors) may raise methadone levels.
Grapefruit juice inhibits CYP3A4 and may increase methadone's effects.

Preparations Of The Drug

Methadone Hydrochloride injectable solution available for intravenous, intramuscular, and subcutaneous use.
Methadone oral concentrate solution for precise volumetric dosing.
Methadone oral solution in flavored formulations facilitating ease of administration.
Oral tablets commonly available in 5 mg, 10 mg strengths for maintenance or analgesic dosing.
Dispersible tablets (e.g., Methadone Diskets) designed to dissolve rapidly in liquid for patients with swallowing difficulties.
Methadone sugar-free syrup formulation available for patients sensitive to sugars or with diabetes.
Methadose brand formulations, including oral concentrate and tablets, supplied for opioid substitution therapy.
Dolophine branded products available in multiple dosage forms for pain and addiction management.
Methadone powder form used in compounding or manufacturing settings.
Premeasured liquid dosing devices supplied with oral concentrate to ensure accurate dosing.
Varied packaging options to suit clinical and outpatient treatment settings.
Strict labeling and tamper-evident packaging mandated due to high abuse potential.
Formulations comply with Schedule II controlled substance regulations in the US.
Storage recommendations emphasize room temperature, protection from moisture and light.
Disposal guidelines recommend use of drug take-back programs or flushing per FDA recommendations to prevent accidental ingestion.